加载中
CRISPR Therapeutics AG (CRSP) is a biotechnology firm dedicated to pioneering gene-based medicines for severe diseases. The company achieves this through its exclusive Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) technology, which enables precise and targeted alterations to an organism's genetic code. Its extensive pipeline includes therapeutic candidates spanning multiple medical areas, such as blood disorders (hemoglobinopathies), various cancers (oncology), regenerative medicine, and rare conditions. The company's flagship investigational therapy is CTX001, an ex vivo CRISPR gene-edited treatment. This therapy aims to benefit patients with transfusion-dependent beta-thalassemia or severe sickle cell disease by modifying their own hematopoietic stem cells to markedly boost the production of fetal hemoglobin within red blood cells. CRISPR Therapeutics is also advancing several other genetically engineered allogeneic (donor-sourced) CAR-T investigational therapies: CTX110, designed to combat cluster of differentiation 19-positive malignancies; CTX120, which targets B-cell maturation antigen for multiple myeloma that has relapsed or proven resistant to previous treatments; and CTX130, focused on Cluster of Differentiation 70 for a spectrum of solid tumors and blood cancers. Furthermore, the company is developing VCTX210, an immune-evasive, gene-edited stem cell-derived product candidate for treating type 1 diabetes. It is also pursuing various in vivo gene-editing initiatives aimed at addressing disorders affecting the liver, lungs, muscles, and central nervous system. The company has forged strategic alliances with significant partners, including Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was established in 2013 and maintains its headquarters in Zug, Switzerland.
收盘时
US$50.10
−US$1.45 · -2.81%
盘后
US$50.22
+US$0.12 · +0.24%
10月13日 18:43 ET
盘中时间采用ET。市场数据可能有所延迟。
CRISPR Therapeutics AG (CRSP) is a biotechnology firm dedicated to pioneering gene-based medicines for severe diseases. The company achieves this through its exclusive Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) technology, which enables precise and targeted alterations to an organism's genetic code. Its extensive pipeline includes therapeutic candidates spanning multiple medical areas, such as blood disorders (hemoglobinopathies), various cancers (oncology), regenerative medicine, and rare conditions. The company's flagship investigational therapy is CTX001, an ex vivo CRISPR gene-edited treatment. This therapy aims to benefit patients with transfusion-dependent beta-thalassemia or severe sickle cell disease by modifying their own hematopoietic stem cells to markedly boost the production of fetal hemoglobin within red blood cells. CRISPR Therapeutics is also advancing several other genetically engineered allogeneic (donor-sourced) CAR-T investigational therapies: CTX110, designed to combat cluster of differentiation 19-positive malignancies; CTX120, which targets B-cell maturation antigen for multiple myeloma that has relapsed or proven resistant to previous treatments; and CTX130, focused on Cluster of Differentiation 70 for a spectrum of solid tumors and blood cancers. Furthermore, the company is developing VCTX210, an immune-evasive, gene-edited stem cell-derived product candidate for treating type 1 diabetes. It is also pursuing various in vivo gene-editing initiatives aimed at addressing disorders affecting the liver, lungs, muscles, and central nervous system. The company has forged strategic alliances with significant partners, including Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was established in 2013 and maintains its headquarters in Zug, Switzerland.
日内区间
当前US$50.10
52周区间
当前US$50.10
盘中时间采用ET。市场数据可能有所延迟。
CRISPR Therapeutics AG (CRSP) is a biotechnology firm dedicated to pioneering gene-based medicines for severe diseases. The company achieves this through its exclusive Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) technology, which enables precise and targeted alterations to an organism's genetic code. Its extensive pipeline includes therapeutic candidates spanning multiple medical areas, such as blood disorders (hemoglobinopathies), various cancers (oncology), regenerative medicine, and rare conditions. The company's flagship investigational therapy is CTX001, an ex vivo CRISPR gene-edited treatment. This therapy aims to benefit patients with transfusion-dependent beta-thalassemia or severe sickle cell disease by modifying their own hematopoietic stem cells to markedly boost the production of fetal hemoglobin within red blood cells. CRISPR Therapeutics is also advancing several other genetically engineered allogeneic (donor-sourced) CAR-T investigational therapies: CTX110, designed to combat cluster of differentiation 19-positive malignancies; CTX120, which targets B-cell maturation antigen for multiple myeloma that has relapsed or proven resistant to previous treatments; and CTX130, focused on Cluster of Differentiation 70 for a spectrum of solid tumors and blood cancers. Furthermore, the company is developing VCTX210, an immune-evasive, gene-edited stem cell-derived product candidate for treating type 1 diabetes. It is also pursuing various in vivo gene-editing initiatives aimed at addressing disorders affecting the liver, lungs, muscles, and central nervous system. The company has forged strategic alliances with significant partners, including Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was established in 2013 and maintains its headquarters in Zug, Switzerland.
日内区间
当前US$50.10
52周区间
当前US$50.10
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 351万 USD | 3500万 USD | 3.7亿 USD | 43.6万 USD | 9.13亿 USD |
| 销货成本 | 2.33亿 USD | 1.1亿 USD | 1.3亿 USD | 1.1亿 USD | 1.01亿 USD |
| 毛利 | −2.29亿 USD | −7525万 USD | 2.4亿 USD | −1.1亿 USD | 8.12亿 USD |
| 研究与开发 | 2.65亿 USD | 3.21亿 USD | 3.87亿 USD | 4.62亿 USD | 3.41亿 USD |
| 销售、一般及管理费用 | 7354.2万 USD | 7297.7万 USD | 7616.2万 USD | 1.02亿 USD | 9969万 USD |
| 营业费用 | 3.39亿 USD | 3.91亿 USD | 4.62亿 USD | 5.63亿 USD | 4.38亿 USD |
| 折旧和摊销 | 1947.9万 USD | 1925.9万 USD | 1983.7万 USD | 2417.2万 USD | 1795.3万 USD |
| 营业利润 | −5.68亿 USD | −4.67亿 USD | −2.23亿 USD | −6.73亿 USD | 3.74亿 USD |
| 净利润 | −5.82亿 USD | −3.66亿 USD | −1.54亿 USD | −6.5亿 USD | 3.78亿 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$67.83
上涨空间 35.39%报告持有此股票敞口的交易所交易基金。
ARK Innovation ETFARKK2.71亿4.16%79.17亿 USD0.75%US$87.17-0.97%
State Street SPDR S&P Biotech ETFXBI1.46亿1.42%103.03亿 USD0.35%US$146.8-3.04%
iShares Russell 2000 ETFIWM1.19亿0.16%787.4亿 USD0.19%US$276.7-0.43%
ARK Genomic Revolution ETFARKG1.14亿5.53%22.19亿 USD0.75%US$48.51-1.96%
Vanguard Extended Market ETFVXF6392.04万0.07%954亿 USD0.05%US$232.54-0.42%
iShares Russell 2000 Value ETFIWN3726.37万0.27%137.49亿 USD0.24%US$210.99-0.05%
iShares Biotechnology ETFIBB3607.18万0.33%108.2亿 USD0.44%US$200.02-2.08%
Vanguard Russell 2000 ETFVTWO3053.73万0.17%180亿 USD0.06%US$111.77-0.45%ARK Innovation ETFARKKState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMARK Genomic Revolution ETFARKGVanguard Extended Market ETFVXFiShares Russell 2000 Value ETFIWNiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
